Table 2 Geometric mean level (GML; 95% CI) in milligrams per liter and percentage of patients with protective antibody levels for both 23F and 6B in different treatment groups at vaccination, at 4 to 6 weeks, and at 1
| Â | RA on methotrexate | RA on anti-TNF as monotherapy | RA on anti-TNF+MTX | SpA on anti-TNF as monotherapy | SpA on anti-TNF+MTX | SpA on NSAID/analgesics |
|---|---|---|---|---|---|---|
At vaccination | Â | Â | Â | Â | Â | Â |
Patient number (n) | 85 | 79 | 89 | 83 | 83 | 86 |
GML (95% CI) for 23F | 0.7 (0.5-1.1) | 0.6 (0.4-0.8) | 0.7 (0.5-0.9) | 0.7 (0.5-0.9) | 0.8 (0.6-1.2) | 0.97 (0.7-1.4) |
GML (95% CI) for 6B | 2.0 (1.4-2.8) | 1.4 (0.9-2.0) | 1.5 (1.1-2.9) | 1.5 (1.1-2.1) | 1.7 (1.1-2.5) | 2.9 (2.1-4.0) |
4 to 6 weeks of follow-up | ||||||
GML (95% CI) for 23F | 1.9 (1.3-2.6) | 1.9 (1.3-2.7) | 1.4 (1.1-1.9) | 3.1 (2.2-4.5) | 2.5 (1.8-3.5) | 6.4 (4.5-9.1) |
GML (95% CI) for 6B | 3.5 (2.5-4.9) | 3.6 (2.5-5.3) | 2.3 (1.7-3.2) | 4.8 (3.3-6.9) | 3.0 (22.1-4.4) | 9.5 (6.7-13.6) |
Percentage of patients with protective antibody levels for both 23F and 6B | 67% | 58% | 52% | 78% | 65% | 84% |
1.5-year follow-up | ||||||
Patient number (n) | 57 | 50 | 56 | 47 | 49 | 43 |
GML (95% CI) for 23F | 0.6 (0.4-0.8) | 0.5 (0.3-0.8) | 0.4 (0.3-0.5) | 1.0 (0.6-1.6) | 0.8 (0.5-1.3) | 2.0 (1.3-3.0) |
GML (95% CI) for 6B | 1.2 (0.7-1.9) | 1.0 (0.6-1.7) | 0.6 (0.4-1.0) | 1.4 (0.9-2.1) | 1.0 (0.6-1.6) | 2.8 (1.7-4.6) |
Percentage of patients with protective antibody levels for both 23F and 6B | 40% | 32% | 20% | 60% | 49% | 70% |
1.5-year follow-up/4 to 6 weeks of follow-up | ||||||
Relative ratio of protective antibody levels | 0.61 | 0.55 | 0.38 | 0.77 | 0.75 | 0.84 |